MedImmune plans to ask the FDA for clearance to market its inhalable flu vaccine to children and infants as young as six months. A late-stage trial demonstrated that CAIV-T lowered the risk of flu by 55 percent in children compared to standard injectable vaccines. CAIV-T is MedImmune's follow up to FluMist, which has been a reoccurring disappointment to the drug developer. MedImmune plans to file the supplemental application by June.
- read the AP report on CAIV-T